Our story

Our story is one of dedication to patients and to scientific excellence. Over the course of the past three decades, we’ve evolved into a multi-platform cancer company. Today, we are innovating with both small molecules and biotherapeutics to build a diversified portfolio of cancer treatments that give patients hope for the future.

Building a legacy of excellence in oncology innovation

The Exelixis story began in 1994 when our prominent team of founding scientists set out to use model system genetics to systematize drug discovery. This vision ultimately resulted in our flagship commercial product, CABOMETYX® (cabozantinib), and has served as the foundation for our journey to discover and develop next-generation cancer treatments, driven by our relentless pursuit of results for the patients we serve. We’ve redefined the role of small molecule therapeutics – alone and in combination with immune checkpoint inhibitors – working with clinicians to try to set new standards of care for multiple cancer types. These efforts, combined with our development and commercialization partnerships across the globe, extend our reach and impact to more patients. 

Reinvesting to give more patients hope

We take a comprehensive approach to treating cancer that harnesses decades of robust investment and partnerships, rigorously assessing assets through all stages of development and only advancing programs that meet our high bar. Fueled by the commercial success of CABOMETYX® (cabozantinib), we have invested in a very disciplined manner in our early-stage pipeline to fuel long-term growth. This has enabled us to build a clinically differentiated pipeline of small molecules and biotherapeutics, including antibody-drug conjugates, to target an expanding range of tumor types using multiple modalities and mechanisms of action. 

Expanding for the future

To meet the needs of a multi-compound product portfolio and global business, we continue to scale our organizational and operational capacity across all functions. Over the past several years, we have expanded our corporate headquarters and enhanced our state-of-the-art laboratories at our Bay Area campus. We have established an East Coast presence to complement our extensive West Coast discovery and development capabilities. Our growth also includes expanding our experienced field-based team to ensure physicians and patients have access to our treatments. These commitments lay the groundwork for future growth, enabling us to deliver faster on behalf of patients on a global scale.

You are now leaving the exelixis.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.